TIGER Trial Demonstrates High Safety and Efficacy for World’s First Adjustable Thrombectomy Device
24.3.2021 18:18:00 EET | Business Wire | Press release
The first adjustable, fully visible stent retriever shows superiority over conventional stent retrievers in a multicenter trial. The late breaking results were recently presented at the International Stroke Conference and published online in the journal Stroke. The TIGER Trial demonstrates a statistically significant 11-point improvement in the ability to restore blood flow to the brain during ischemic stroke and equivalent safety for the TIGERTRIEVER™ device compared to existing self-expanding stent retrievers.
“The trial confirmed that the TIGERTRIEVER is not only safe and effective, but demonstrably improved outcomes over similar trials testing previous technology,” observed Jeffery Saver, MD, FAHA, Professor of Neurology and Director of the Comprehensive Stroke and Vascular Neurology Program at UCLA. “TIGERTRIEVER is an important advance in stroke treatment devices and a win for patients.”
Stent retriever devices (“stentrievers”) are the gold standard in treating large vessel ischemic strokes. Delivered minimally invasively through the vasculature, they expand into the clot to capture and remove the blockage as the device is retrieved. Prior to TIGERTRIEVER, the diameter and force of these devices were non-adjustable. With TIGERTRIEVER, physicians control the diameter and force as needed in response to real-time anatomical and procedural information. This ability to respond to situational feedback is known as intelligent control. The TIGER Trial concludes that these improvements provide meaningful benefit when removing the clot and treating stroke.
The TIGER Trial ended early after overwhelming effectiveness with 160 patients enrolled at 17 centers in the US and Israel. The trial demonstrates 84.6% revascularization success, compared to a 73.4% average from 6 recent pivotal stent retriever trials. This improvement translates to significantly better patient outcomes, with 58% of patients living independently after 90 days versus an average of 43% of patients from the previous device trials. Additionally, the TIGER Trial shows improved safety, with an 18.1% primary safety score versus a 20.4% historical average.
“TIGERTRIEVER’s intelligent control represents a new generation of stent retrievers as shown by the highest revascularization success rate of similar stent retriever trials,” said Walid Haddad, Chief Clinical Officer at Rapid Medical. “We applaud the work performed by our national principal investigators, Drs. Jeffery Saver of UCLA and Rishi Gupta of Wellstar Health System in Atlanta, GA, and all of our investigators and clinical site staff.”
About Rapid Medical
Rapid Medical develops the premier responsive interventional devices for neurovascular diseases such as ischemic and hemorrhagic stroke. Utilizing novel manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the intravascular environment and have greater control over procedural outcomes. TIGERTRIEVER™, COMANECI™ and COLUMBUS™/DRIVEWIRE are CE marked. COMANECI™ and DRIVEWIRE are also FDA approved. More information is available at www.rapid-medical.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005703/en/
Contact information
Ronen Eckhouse
+972-72-2503331
ronen@rapid-medical.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AIRS Medical Welcomes Strategic Growth Investment from TA Associates to Accelerate Global Growth in AI-Powered MRI Solutions16.6.2026 17:00:00 EEST | Press release
AIRS Medical (“the Company”), a global leader in AI solutions for medical imaging, today announced a strategic growth investment from TA Associates (“TA”), a leading global private equity firm. The investment will help fuel AIRS Medical’s next phase of global expansion, advancement of its AI-powered radiology technology solutions and ongoing product innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616325248/en/ Founded in 2018, AIRS Medical develops AI-native magnetic resonance imaging (“MRI”) acceleration and reconstruction software designed to support MRI speed, image quality and workflow performance. Healthcare organizations and leading academic institutions are adopting AIRS Medical's technologies to expand imaging capacity and improve patient access. Today, the Company supports more than 1,700 healthcare institutions across over 40 countries, with its AI technologies utilized in more than 6 million MRI exam
Svante’s Solid Sorbent Filter Technology Named to Fast Company’s 2026 World Changing Ideas Awards List16.6.2026 17:00:00 EEST | Press release
Svante Technologies Inc. (Svante), a purpose-driven integrated carbon management company, today announced that its nanoengineered solid sorbent filter technology has been named to Fast Company’s 2026 World Changing Ideas list, one of the world’s most selective recognitions for innovations tackling climate and sustainability challenges. The honour recognizes Svante’s proprietary filter platform, which enables high-performance capture and removal of CO₂ from industrial emissions and the air, as well as other critical gas separation applications, particularly where chemical processes do not perform well. This year’s awards, featured on fastcompany.com, highlight 191 outstanding projects across 14 categories. A panel of Fast Company editors and reporters evaluated more than 1,500 entries based on their impact, sustainability, design, creativity, scalability, and ability to improve society. “This recognition underscores the commercial and societal importance of Svante’s approach to carbon c
Gurobi's Research Leadership Recognized Across Leading Scientific Organizations16.6.2026 16:00:00 EEST | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced recognitions received by Dr. Edward Rothberg and Dr. Andreas Wächter from leading academic and industry organizations for research that has had lasting impact on the field of optimization. “Gurobi was founded on a commitment to rigorous, applied optimization research,” said Dr. Oliver Bastert, CTO, Gurobi. “And these recognitions are a reflection of that legacy. The foundational work that Ed and Andreas produced continues to shape the field, and that same spirit of scientific innovation drives everything we do today.” Dr. Edward Rothberg, co-founder and Chairman of the Board at Gurobi, was recently honored with the INFORMS Test of Time Paper Award for his paper, “An Evolutionary Algorithm for Polishing Mixed Integer Programming Solutions.” The paper introduced a novel approach to finding high-quality solutions to difficult MIP problems — expanding what was possible within the MIP framework and inf
New CSC Report Illustrates How AI Is Affecting Enterprise Security Leaders16.6.2026 16:00:00 EEST | Press release
CSC, an enterprise-class domain registrar and world leader in mitigating brand, fraud, domain, and domain name system (DNS) threats, today released new research on how chief information security officers (CISOs) are adapting to an evolving artificial intelligence (AI) ecosystem while managing traditional cyber threats, such as DNS outages. According to CSC’s CISO Outlook 2026 report, 73% of respondents say AI presents more of an opportunity than a risk for cybersecurity. However, these security leaders continue to face challenges in addressing attacks, including AI-powered domain generation algorithms (DGAs), which 86% of respondents cite as a threat. To thoroughly understand the CISO perspective on today’s cybersecurity landscape, CSC surveyed 300 senior executives—including CISOs, chief technology officers (CTOs), chief information officers (CIOs), and heads of cybersecurity—in Q1 2026. Key findings from the CISO Outlook 2026 report include: Respondents ranked the top three threats i
Airship Helps DIE ZEIT Turn Silent Advocates into 4.9-Star Rating16.6.2026 16:00:00 EEST | Press release
Airship, the mobile-first customer experience company, today announced that DIE ZEIT, one of Germany’s largest and most prestigious publishers, has successfully transformed its mobile app presence, lifting the Google Play app store rating from 2.7 stars in early 2026 to a near-perfect 4.9 stars. At a time when many traditional publishers are seeing readership numbers plummet, DIE ZEIT is growing — reaching an all-time high circulation in 2025 and building a digital ecosystem around the brand. The majority of the publication’s readers are now digital, but the publication’s app store rating for DIE ZEIT didn’t match this momentum. DIE ZEIT was up against a universal challenge faced by digital product teams and customer experience executives globally: the "silent advocate" problem. While highly satisfied customers rarely pause their reading experience to leave public reviews, users facing temporary, one-off frustrations are highly motivated to voice complaints. This discrepancy often lead
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom